Biogena Group Invest AG (BIO)

Overview

Opyl Limited is a forward-thinking healthcare technology company based in Milsons Point, Australia, focused on enhancing the healthcare experience through the development of innovative digital tools. Initially incorporated in 1994 as ShareRoot Limited, the company underwent a significant rebranding to Opyl Limited in December 2019. Its core mission is to leverage advanced technologies, particularly artificial intelligence (AI), to revolutionize clinical trial processes for a range of stakeholders including pharmaceuticals, MedTech organizations, government bodies, and healthcare institutions. Opyl Limited's solutions are designed to optimize clinical trial designs, improve success prediction accuracy, and streamline the overall trial process, thereby speeding up the development of new treatments and therapies.

Products and Services

• TrialKey

TrialKey stands as Opyl Limited's premier AI-driven platform aimed at revolutionizing the clinical trial landscape. Designed to simulate and optimize trial designs, TrialKey serves a broad spectrum of applications from pharmaceuticals and medical devices to alternative therapies and novel conditions. This platform's predictive capabilities allow it to forecast trial success, significantly mitigating risks and enhancing the efficiency of clinical research endeavors.

• TrialGen

An additional pillar of Opyl's innovative suite, TrialGen, is an AI-powered tool that streamlines the clinical trial design process. Tailored for biopharma, MedTech companies, government agencies, and healthcare organizations, TrialGen automates and simplifies the intricate steps involved in trial design. Its capabilities ensure that clinical studies are not only more effectively structured but also aligned with regulatory standards and patient needs, thereby maximizing the potential for successful outcomes.